LDOS · Q4 2025 Earnings
CautiousLeidos
Reported February 17, 2026
30-second summary
Q4 revenue fell 4% YoY to $4.21B as the six-week government shutdown compressed the quarter, but FY25 still landed at $17.17B (+3%) with non-GAAP EPS of $11.99 — $0.24 above the high end of the raised guide — and adjusted EBITDA margin of 14.1% (Q4 alone 13.2%). FY26 guidance is the tell: revenue $17.5–17.9B (up to 4% growth), EPS $12.05–12.45 (midpoint $12.25, roughly flat to FY25 actual), EBITDA margin stepped back to "mid 13s" from FY25's 14.1% print — a ~60bps step-down — with management explicitly framing growth as back-loaded toward "approaching double digits" exiting the year. After two consecutive quarters of raises, the algorithm has flattened — the question for 2026 is whether the H2 acceleration management is promising materializes from the $7B of Q4-slipped awards, $20B pending pipeline, and 1.3 book-to-bill, or whether the ~60bps mid-13s margin step-down is the leading indicator.
Headline numbers
EPS
Q4 FY2025
$2.76
Revenue
Q4 FY2025
$4.21B
-4.0% YoY
Gross margin
Q4 FY2025
17.6%
Free cash flow
Q4 FY2025
$0.45B
Operating margin
Q4 FY2025
11.2%
Key financials
Q4 FY2025| Metric | Q4 FY2025 | YoY | Q3 FY2025 | QoQ |
|---|---|---|---|---|
| Revenue | $4.21B | -4.0% | $4.47B | -5.9% |
| EPS | $2.76 | — | $3.05 | -9.5% |
| Gross margin | 17.6% | — | 18.4% | -80bps |
| Operating margin | 11.2% | — | 12.0% | -80bps |
| Free cash flow | $0.45B | — | $0.68B | -33.5% |
Guidance
Strong FY2025 beats on EPS and EBITDA margin; FY2026 guidance is conservative with flat-to-low-single-digit EPS growth but improved operating cash flow, signaling a deceleration cycle after raised 2025 results.
Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.
Actuals vs prior guidance
| Metric | Period | Prior guide | Actual | Δ | Result |
|---|---|---|---|---|---|
| Revenue | FY2025 | $17.00 - $17.25 billion | $17.174 billion | +0.024 billion above midpoint; within range | Beat |
| Non-GAAP Diluted EPS | FY2025 | $11.45 - $11.75 | $11.99 | +$0.24 above high end | Beat |
| Adjusted EBITDA Margin | FY2025 | High 13% | 13.2% | +~20bps above high-13s guidance | Beat |
New guidance
| Metric | Period | Guide | YoY |
|---|---|---|---|
| Revenue | FY2026 | $17.5 - $17.9 billion | +1.8-4.2% YoY |
| Non-GAAP Diluted EPS | FY2026 | $12.05 - $12.45 | +0.5-3.8% YoY |
| Adjusted EBITDA Margin | FY2026 | Mid 13% | — |
| Cash Flows Provided by Operating Activities | FY2026 | Approximately $1.75 billion | +6.1% YoY |
Segment KPIs
Q4 FY2025| Segment | Q4 FY2025 | YoY |
|---|---|---|
| National Security & Digital | $1.846B | -3.0% |
| Health & Civil | $1.205B | -9.0% |
| Commercial & International | $0.61B | +1.0% |
| Defense Systems | $0.546B | +1.0% |
Other KPIs
Q4 FY2025| Segment | Q4 FY2025 |
|---|---|
| Adjusted EBITDA | $556 million |
| Adjusted EBITDA Margin | 13.2% |
| Net Bookings | $5.6 billion |
| Book-to-Bill Ratio | 1.3 |
| Total Backlog | $49.0 billion |
| Funded Backlog | $9.7 billion |
| Operating Cash Flow | $495 million |
| Free Cash Flow Conversion | 127% |
Management tone
Narrative arc: DOGE freeze (Q1) → logjam breaking up (Q2) → awards in the numbers (Q3) → execution mode with tripled capex (Q4).
The shift from Q3 to Q4 is from "thriving through adversity" to "redefining what it means to be a national security company" — a frame that has migrated from operational to transformational. Bell's anchor line — "We are now firmly in strategy execution mode for our North Star 2030 strategy with a strong bias for velocity and a strong productive sense of urgency" — pairs with the announcement that capex is tripling to $350M, that two leadership changes were made, and that "co-investment opportunities with this administration around critical war fighting and national needs" are being negotiated. This is markedly more aggressive than the August "logjam breaking up" framing or the November "awards picking up." The question is whether this aggression is being matched by 2026 guidance — and the answer is no, which is the dissonance worth pricing.
The margin narrative has shifted from "incremental improvement" to "fundamental business model change." Bell's claim that "Our margin expansion journey has meaningfully changed how we view what is possible, and that change permeates the entire company" with "six consecutive quarters of positive net EACs" is the most confident margin framing the company has offered. But the FY26 guide steps margin back ~60bps to mid-13s from the 14.1% print of FY25 — meaning the cultural confidence is not being underwritten by the numerical guide. Either the guide is sandbagged or the narrative is ahead of the reality; investors should not assume both can be true.
The capital allocation pivot is more aggressive than any prior quarter. Q2 framed M&A as "now part of the playbook"; Q3 added the KUDU deal with $400M in cross-pipeline opportunities; Q4 announces tripled capex, the Entrust energy acquisition, no buybacks in the 2026 guide, and 2.6x pro-forma leverage. Bell's framing — "organic and inorganic investments will become more prevalent in our capital management strategy" — is a clean shift away from the buyback-and-dividend posture of 2024. Investors modeling 2026 EPS off historical share-count attrition should mark to no buybacks as the base case.
Administration alignment language has notably retreated. Prior calls leaned heavily on "alignment with the priorities of the administration"; this quarter's prepared commentary is more muted on that frame, even as capex tripling and "co-investment opportunities" suggest the alignment is operationally deeper. This is either deliberate downplay to manage political-risk optics or an acknowledgment that the policy-to-bookings conversion is taking longer than the Q2 thaw narrative implied. Either reading argues for more scrutiny on named task orders, not less.
The risks management itemized — six-week shutdown impact on Q4, managed health headwinds before inflection, airborne programs margin ebb, fixed-price homeland execution risk, $90M Section 174 cash headwind — are more specific and more numerous than in any prior call this year. The specificity is healthy disclosure; the volume is the tone signal. When management lists five named risks in a forward outlook, the implicit framing is that the year requires more execution discipline than the headline guide suggests.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Seth Seethman · JP Morgan
What investment areas will receive additional capex, how does that support defense business ramp, and what is the relationship to co-investment opportunities with the Department of War? Also, how should we model the early-year weakness given the guidance for stronger growth exiting the year?
Leidos is investing in co-development opportunities with DoD and FAA modernization, particularly in maritime growth, integrated air defense, and hypersonics. Lower growth expected in H1 2026 with acceleration in H2 driven by Golden Dome initiatives, FAA modernization catalysts, and new program ramp-ups. $7 billion in awards slipped from Q4 into Q1, with $20 billion pending awards and $49 billion backlog.
John Godden · Citi
Given strong book-to-bill performance without a dip, can you elaborate on expectations for award activity acceleration and the shape of that acceleration through the year?
Management attributes 1.3x book-to-bill to deliberate three-year investment in growth function and new leadership. Emphasizes robust pipeline, strong re-compete and takeaway win rates, and highest next-12-month pipeline submittal activity. Three-quarters of 2026 bid pipeline expected to target new business and takeaways versus re-competes.
Gautam Khanna · TD Cowan
What are expectations for VA medical exam recompete terms and timing, and what is Leidos doing to sustain profitability given typical margin pressure in recompetes?
Leidos maintains commitment to health business despite entry of fourth vendor and potential work-share reallocation. Growth focuses are rural health transformation and behavioral/integrated health. VA medical disability exam RFP expected mid-2026. Management expects to sharpen pencil while maintaining profitability, with health business projected to achieve above 20% margins beyond 2026.
Colin Canfield · Cantor
Where is the greatest conservatism in 2026 guidance, what key milestones could trigger upside, and how should we bridge 2026 outperformance into 2027 expectations?
Greatest conservatism in defense segment upside (if DoD funding decisions, Golden Dome, maritime accelerate) and FAA opportunities (if customer decisions pull forward). Health margin conservatism built in around potential volume reallocation. No one-time items included in guidance; momentum from 2026 outperformance expected to carry into 2027.
Ken Herbert · RBC Capital Markets
How are you thinking about capital allocation, incremental M&A opportunities, and buyback expectations given 2.6x pro forma leverage after Entrust?
Management prioritizes organic and inorganic investments aligned with North Star 2030 strategy. No buybacks assumed in 2026 guidance; capital will focus on growth pillars and Entrust integration. Dividend program continues, with opportunistic shareholder-friendly deployments evaluated. Will maintain rigorous ROI analysis on all capital deployment.
Answers to last quarter's watch list
What to watch into next quarter
Conversion of the $7B Q4-slipped awards in Q1. Management told analysts the slippage was timing, not demand-loss. Watch for a Q1 book-to-bill print and named definitizations — Q1 needs to show the slipped awards landing, otherwise the H2 acceleration thesis loses its leading indicator.
Defense Systems revenue trajectory after the +1% Q4 print. Seven consecutive quarters of HSD-LDD growth ended this quarter. Watch whether Q1 reaccelerates or whether the airborne-margin-ebb commentary signals a broader Defense Systems pause. A second sub-mid-single-digit quarter would meaningfully damage the segment-mix thesis.
H&C inflection timing. Q4 printed -9%. Management frames the headwinds as near-term with inflection ahead. Watch for the specific quarter management points to for the inflection — and whether Q1/Q2 prints show sequential improvement toward positive YoY, or whether the segment requires the full year to recover.
Entrust close and post-close guidance update. Management explicitly excluded Entrust from FY26 guidance, with a planned post-close update in Q2. Watch the size of the guidance lift versus what sell-side has triangulated from the deal disclosure — under-delivery against expectations would imply the underlying organic guide was tighter than the headline suggested.
Margin walk from 14.1% FY25 actual to mid-13s FY26 guide. The ~60bps step-back is the cleanest "hidden cut" in the print. Watch Q1 and Q2 EBITDA margin prints — if margin holds in the high-13s through H1, the FY26 guide is sandbagged; if margin compresses toward mid-13s in H1, the guide is realistic and the FY25 exit rate was the peak.
EPS leverage at H2 revenue acceleration. The FY26 EPS midpoint of $12.25 is essentially flat against FY25's $11.99 despite revenue growth and no buybacks. Watch whether H2 EPS leverage materializes proportionate to the promised "approaching double digits" revenue exit — if it doesn't, the operating leverage story that anchored FY25's beats is structurally weakening.
Sources
- Leidos Q4 2025 Press Release — https://www.sec.gov/Archives/edgar/data/1336920/000133692026000028/ldos1022026ex991.htm
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.